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Abstract
Discovering novel drugs for curing cancer and infectious diseases is the prime interest of several research areas now.
Marine sessile invertebrates have produced secondary metabolites, a lot of which are utilized as novel pharmaceutical
agents with diverse effects whether anti-cancer or anti-microbial. Ascidians are marine sessile animals (phylum:
Chordata, class: Ascidiacea). Various anti-cancer, anti-viral, and anti-bacterial components are obtained from different
bioactive compounds belonging to ascidian species and are in different stages of clinical trials. In this study, ﬁve
ascidian species which are Polyclinum constellatum, Botryllus eilatensis, Didemnum sp., Symplegma rubra, and Styela
canopus were collected from two coastal sites in Egypt. These specimens were utilized for preparing extracts using
organic and inorganic solutions. Crystal violet assay using human breast cancer cell line was performed for evaluation
cytotoxic activity of dried extracts, besides the diffusion agar technique to assess anti-microbial activity using 6-type
fungi: Aspergillus fumigatus, Aspergillus ﬂavus, Candida albicans, Syncephalastrum racemosum, Candida tropicalis, and
Penicillium expansum, Gram-positive Bacteria: Staphylococcus aureus, Bacillus subtilis, and Streptococcus mutants, and
Gram-negative bacteria: Enterobacter cloacae, Escherichia coli, and Proteus vulgaris. Two ascidian species, Didemnum sp.
and S. rubra, showed signiﬁcant cytotoxicity against human breast cancer cell line while other species showed moderate
cytotoxicity. All investigated ascidian species have antibacterial compounds toward S. aureus and B. subtilis. The only
species exhibited antibacterial activity against the fungus A. fumigatus was Botryllus eilatensis Didemnum sp. has
exhibited activity against seven microbes, while S. canopus, Botryllus eilatensis, S. rubra, and P. constellatum have
exhibited activities against 4,5,4, & 2 microbes from twelve used microbes, respectively. Therefore, ascidian species are
excellent species for further studies to discover new pharmaceutical agents in Egypt.
Keywords: Bioactive compounds, Secondary metabolites, Human breast cancer cell line, Infectious diseases, Ascidians

1. Introduction

T

he most disease deaths in developed countries
come as a result of cancer [1], besides nearly
one half of entire mortality was estimated in tropical
world owing to infectious diseases which constitute
a serious menace to our health because of the unavailability of vaccines or limited chemotherapy [2].
Pharmacodynamics of available antimicrobial
agents considerably has limited regimes, both in
antimicrobial spectrum and side effects. The misuse
of anti-microbial drugs has resulted in increasing

resistance of emerging and re-emerging pathogenic
microbes [3,4].
For these causes, a desire to discover new compounds with novel therapeutic mechanisms has
augmented. In this regard, natural products have
achieved several accomplishments and served
various purposes well. Extracts of extract natural
products have a visible role in discovering modern
drugs and drug scaffolds for curing different illnesses [5]. Recorded components that have obtained
from marine environments are having bioactive
advantages with various modes of action [6e8]., like
anti-hypertensive, anti-cancer, anti-microtubule,
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cytotoxic, and antibiotic features [9e11]. Various
chemical natures (characteristics) have been implicated in these isolated marine compounds, which
are obtained from sponges, bacteria and other biota.
Examples of these components are alkaloids, terpenoids, phenols, and other secondary metabolites
[12].
The extraction and examination of marine natural
products (MNPs) to be used as pharmaceutical
agents have dramatically augmented owing to
extraordinary marine biodiversity, which in turn, is
far surpassing terrestrial biodiversity. Marine creatures have well-sophisticated and developed physiological and biochemical systems because of an
evolution process, so they can resist severe environmental variables via unique adaptation strategies to still exist and preserve species from
extinction, in addition to they can preserve their
residence place in spite of tough competition with
other countless various species. These species have
elaborated chemical means to avoid falling prey to
their several predators, prevent overgrowth of other
species, or capture motile prey for obtaining the
food. Marine invertebrates and bacteria have produced secondary metabolites, a lot of which have
been utilized as novel pharmaceutical agents with
diverse effects whether anti-inﬂammatory, antibiotics, or anti-cancer [13].
Some of bioactive compounds, which found in
marine invertebrates predominately ascidians and
sponges, are conﬁrmed by FDA and presently utilized in various stages of clinical trials or on the
market as approved drugs [14]. The distinctive life of
sea resulted in the presence of several molecules
only in one source [15], like Jasplakinolide and
Didemnin B only found in species of sponge Jaspis
[16] and genus of ascidian Trididemnum [17],
respectively. Ascidians are the most developed
species of marine ecosystem commonly being used
for identiﬁcation of MNPs. They provide varying
types of bioactive components with predicting propitious implementations in medical area [18]. Ascidians that belong to the class Ascidiacea of the
subphylum Urochordata [19] are leading a sedentary mode of life, they produce secondary metabolites as sponges and bryozoans to protect their
existence and avoid fouling or predating species.
Therefore, they are promising species for scientiﬁc
research of natural products [20].
Promising in vitro active compounds isolated
from diverse species of ascidians, “327 anti-tumor/
cancer, 93 anti-microbial, 16 anti-HIV, 16 Central
Nervous system depression, 15 anti-inﬂammatory
compounds and other important components”,
were recorded during the years 1994e2014 [21]. Five
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Abbreviations
ATCC
American Type Culture Collection
DMEM Dulbecco's modiﬁed Eagle's medium
HEPES buffer
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
IC50
The concentration showed toxic effects in 50% of
intact cells
MCF-7 cells
Human breast cancer cell line
MNPs
Marine Natural Products
NCCLS National Committee for clinical laboratory
Standards
ODc
the mean optical density of untreated cells
ODt
the mean optical density of wells treated with the
tested sample

percent of extant ascidian species from less than
three-thousand species only was utilized for studies
of their chemical diversity and pharmacological
applications. These studies were performed about
“family didemnidae (32%), polyclinidae (22%),
styelidae and polycitoridae (11e12%)” showing
auspicious signs for discovering novel drugs from
marine origins. The most part of drug ﬁelds was
concentrated on investigation MNPs from ascidians
for the treatment of cancer with ratio 64%. The
remaining areas of drug classes were anti-bacterial
(14%), anti-malarial (6%), anti-fungal (3%), anti-inﬂammatory (3%), central nervous system (3%), antiHIV (3%), anti-viral (1%), anti-diabetic (1%), and
anti-oxidant (2%) pharmaceutical agents studied
from 1994 to 2014 [21].
Most of the new ascidian components (>80%)
include nitrogen. Almost 70% of nitrogenous metabolites are alkaloids [22]. These components
frequently show several biological impacts such as
antibiotic, immunosuppressive activities, cytotoxicity, inhibition of topoisomerases and cyclin kinases [23]. Contrary, scarce amount of nonnitrogenous metabolites has been in ascidians and
less signiﬁcant as well [24]. New anti-cancer compounds may be extracted from several ascidian
species [25]. A marine derived alkaloid trabectedin,
which formerly recognized as ecteinascidin-743,
commercial name Yondelis®, obtained from extracts of the ascidian species, Ecteinascidia turbinate,
has been provided for the treatment of soft-tissue
sarcomas [26]. Besides, antimalarial components are
isolated from the solitary ascidians Ascidia sydneiensis, Microcosmus helleri, and Phallusia nigra [27].
In the pharmaceutical industry, large number of
anti-cancer, anti-viral and anti-bacterial compounds
is subject to clinical trial stages [28]. The main
objective of this study is to examine the potential
use of ascidians collected from Egyptian coasts as a
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bio-active isolation source via evaluation antimicrobial and cytotoxic effects of extracts of selected
ascidian species.

2. Results
2.1. Evaluation anti-microbial activity of the ﬁveascidian extracts
Data in Charts (1-3) show that ascidian extracts of
Polyclinum constellatum, Botryllus eilatensis, Didemnum sp., Symplegma rubra, and Styela canopus have

Chart 1. Showed various activities of ascidian extracts: (1) P. constellatum, (2) S. rubra, (3) B. eilatensis, (4) S. canopus and (5)
Didemnum sp. against fungi: (A) A. fumigatus, (B) S. racemosum, (C)
C. tropicalis, (0): No activity.

different activities against fungi, and both Grampositive and negative Bacteria. From 6-type fungi
examined in this study, Aspergillus fumigatus (RCMB
002008), Aspergillus ﬂavus (RCMB 002002), Candida
albicans RCMB 005003 ATCC 10231, Syncephalastrum
racemosum RCMB 016001, Candida tropicalis RCMB
005004 (1), Penicillium expansum RCMB 001001 (1)
IMI 28169, only ﬁve activities have been shown toward three fungi by S. rubra toward C. tropicalis
RCMB 005004 with 12 mm inhibition zone, B. eilatensis toward A. fumigatus (RCMB 002008) with 15
mm inhibition zone, S. canopus toward S. racemosum
RCMB 016001 (1) with 10 mm inhibition zone, and
Didemnum sp. toward S. racemosum RCMB 016001 (1)
and C. tropicalis RCMB 005004 (1) with 12 mm and 17
mm inhibition zones, respectively.
For the used gram-positive Bacteria: Staphylococcus
aureus, Bacillus subtilis, and Streptococcus mutants, and
gram-negative bacteria: Enterobacter cloacae, Escherichia coli, and Proteus vulgaris, the ﬁve ascidian extracts have afforded activity with the different
degrees toward 2 g-positive bacteria S. aureus and B.
subtilis. The highest activity was from Didemnum sp.
with inhibition zones of 17 & 10 mm respectively,
whereas the lowest activity was from P. constellatum
with inhibition zones of 10 & 8 mm, respectively.
From 3 types of investigated gram-negative bacteria,

Chart 2. Showed various activities of ascidian extracts: (1) P. constellatum, (2) S. rubra, (3) B. eilatensis, (4) S. canopus and (5) Didemnum sp. against
gram-positive Bacteria: (A) S. aureus, (B) B. subtilis, (C) S. mutants, (0): No activity.

Chart 3. Showed various activities of ascidian extracts: (1) P. constellatum, while (2) S. rubra, (3) B. eilatensis, (4) S. canopus and (5) Didemnum sp.
against gram-negative bacteria: (A) E. cloacae, (B) E. coli, (C) P. vulgaris, (0): No activity.
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S. rubra has activity against E. coli with inhibition
zone of 10 mm. B. eilatensis has activity against E.
cloacae and E. coli with inhibition zones of 8 & 12
mm, respectively. S. canopus has activity against P.
vulgaris. Didemnum sp. has activity against E. cloacae,
E. coli, and P. vulgaris with inhibition zones of 12, 11 &
12 mm, respectively. No activity has been displayed
by any of ﬁve ascidian extracts against the four microbes: the three fungi A. ﬂavus, C. albicans and P.
expansum (not shown in fungi chart); and the grampositive bacterium S. mutants.
Plate 1. Evaluation of cytotoxicity against MCF-7 cell line.
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2.2. Evaluation of cytotoxicity against human
breast cancer cell line (MCF-7)
Five ascidian extracts of P. constellatum, B. eilatensis, Didemnum sp., S. rubra, and S. canopus examined against MCF-7 cell line showed cytotoxic
effects with different IC50 results. In ﬁve ascidian
extracts, lowering extract concentrations resulted in
decreasing inhibition effects on MCF-7 and
increasing viability percentage as well. The highest
inhibition against MCF-7 cells was at 500 mg/ml for
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all tested ascidian extracts (Plate 1). Besides, a
graphic plot between cell viability percentages and
various concentrations was constructed for each
ascidian extract for evaluation IC50 values. The
graph was descending also in all ascidian extracts
indicating that cell viability decreased as concentrations increased of each ascidian extract.
The most signiﬁcant IC50 result was showed by
colonial ascidian S. rubra with IC50 value ¼ 17.5 ± 3.2
mg/ml (the most descending graph) while the lowest
one was exhibited by solitary ascidian S. canopus
extract with IC50 value¼178 ± 4.8 mg/ml. Extract of
colonial encrusting Didemnum sp. showed the second signiﬁcant IC50 value¼47.4 ± 1.4 mg/ml. (the
most descending graph after Symplegma rubra
graph) while the last two IC50 values of ascidian
extracts belonging to P. constellatum and B. eilatensis
were 61 ± 0.9 and 79 ± 2.9 mg/ml, respectively.
Therefore, ascidian colonial species showed more
cytotoxic effect than solitary species under these
experimental conditions. The most signiﬁcant species having cytotoxic effects are arranged as follow:
S. rubra > Didemnum sp.> P. constellatum > B. eilatensis > S. canopus.

2.3. Collected ascidian samples
Ascidian samples were collected from two coastal
sites (Port Said and Ismailia) at Suez Canal region
which are affected by ship trafﬁc, the collected
species illustrated in Photos (1-5).

Photo 1. Polyclinum constellatum, colonial species, Ismailia, after 3
days of preserving at e 20  C.
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Photo 2. Symplegma rubra, Colonial species, Port Said, after 6 hours of
collection.
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Photo 4. Styela canopus, Solitary species, Port Said, after 6 hours of
collection.

Photo 5. Didemnum sp. Colonial species, Port Said, after 6 hours of
collection.

3. Discussion
Photo 3. Botryllus eilatensis, Colonial species, Port Said, after 6 hours of
collection.

The most probable cause for a wide geographic
distribution of ascidians has been owing to their
ability to synthesize secondary metabolites that
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greatly assist in surviving process and domination
of several marine communities [29]. According to
UN, marine biodiversity introduces the widespread
availability of promising bioactive components for
treatment of different diseases.
3.1. Antimicrobial activity of ascidian
From previous studies that conﬁrm antimicrobial
activity of ascidians, a high and moderate antibacterial activity has showed in various extracts of
Polyclinum madrasensis (Family: Polyclinidae), and
Phallusia nigra, (Family: Ascidiidae) which are
collected from Tuticorin, Southeast coast of India,
against number of bacterial pathogens to human
like Staphylococcus aureus, Salmonella typhi, S. paratyphi, Klebsiella oxytoca, K. pneumonia, Vibrio cholerae,
Pseudomonas aeruginosa, E. coli, Proteus mirabilis,
Lactobacillus vulgaris. Different solvents were used
such as methanol, dichloromethane, 2-ethoxy
ethanol, acetone, chloroform, n-butanol, ethyl acetate and diethyl ether to prepare extracts. Consequently, ascidians species could be used for
discovering novel antimicrobial agents [30].
In Indonesia, the disk diffusion assay using ﬁve
human pathogenic bacteria, two Gram-positive
bacteria: S. aureus (ATCC 25923), and B. subtilis
(ATCC 6633), in addition three Gram-negative bacteria: E. coli (ATCC 25922), Vibrio cholerae (ATCC
14035), and Pseudomonas aeruginosa (ATCC 10145)
has been showed inhibitory activity by ascidians
(wet weight: from 150 to 200 g) Lissoclinum patella
(Family: Didemnidae), Oxycoryna fascicularis (Family: Clavelinidae), and Didemnum molle (Family:
Didemnidae). Whereas no activity has been found
in Botryllus schlosseri (Family: Styelidae) toward E.
coli. The extracts of both ascidians Oxycoryna fascicularis and Didemnum molle have exhibited the
most active antibacterial activity against Grampositive bacteria S. aureus with inhibition zones of
9.10 and 9.20 mm, respectively, and B. subtilis with
inhibition zones of 9.20 and 10.2 mm, respectively.
The highest activity against Gram-negative bacteria
(E. coli and V. cholerae) was observed in L. patella
extract with inhibition zones of 9.20 and 9.1 mm,
respectively [31].
Besides, the anti-fungal assays of all these Indonesian ascidian extracts (MeOHeCHCl3 3:1 three
times at room temperature) were active against two
tested fungi organisms: Candida albicans (ATCC
10231) and Aspergillus niger (ATCC 16404) with control values, nystatin: 20.3, 15.4 mm, respectively,
while the highest inhibitory activity against C. albicans was demonstrated by Didemnum mole, with 9.1
mm inhibition zone. Other extract values of

ascidians Lissoclinum patella 4.8 mm, 4.3 mm, Oxycoryna fascicularis 5.2 mm, 5.8 mm, and Botryllus
schlosseri (Family: Styelidae) 3.7 mm, 4.1 mm,
respectively [31]. In the study of Konuklugil et al.
[32] the ascidian extract of Ascidiella aspersa (Family:
Ascidiidae) showed a signiﬁcant antimicrobial activity against yeasts (Candida krusei and Candida
parapsilosis).
In this study, the bioactivity examination of
selected ascidian species collected from Egypt that
are: Polyclinum constellatum, family: Polyclinidae;
Symplegma rubra, Botryllus eilatensis, and Styela
canopus., family: Styelidae; Didemnum sp., family:
Didemindae approved presence of various antimicrobial and cytotoxic compounds in these species.
3.1.1. The ascidian Botryllus eilatensis and
Symplegma rubra
Indonesian ascidians Botryllus schlosseri has had
inhibitory activity toward used microbes S. aureus
(ATCC 25923), and B. subtilis (ATCC 6633), V. cholerae (ATCC 14035), and P. aeruginosa (ATCC 10145)
with inhibition zones of 8.6, 7.3, 3.6, & 4.5 mm,
respectively [31]. Therefore, there is an agreement
with our study in the existence of antibacterial
compounds in the genus Botryllus from Egypt toward the two Gram-positive bacteria S. aureus and B.
subtilis.
No activity in previous study of [31] has been
found in B. schlosseri toward E. coli while L. patella
has activity. In this study ascidians S. rubra, B. eilatensis, and Didemnum sp. have bioactive compounds
against E. coli. Therefore, this study differs with [31]
because Botryllus species from Egypt has antibacterial
activity toward E. coli with inhibition zone of 12 mm.
3.1.2. The ascidian Polyclinum constellatum
In Egypt 0.5 kg of the ascidian Polyclinum constellatum (Family: Polyclinidae) was collected from
the Red Sea coast at Safaga and directly frozen. Nine
secondary metabolites have been Isolated and
tested against various organisms. Compound 24methylene cholesterol exhibited promising antitrypanosomal activity with IC50 3.39 ± 0.68 and IC90
6.69 ± 0.78. No signiﬁcant activity of the compounds
has showed against used microbes: bacterial strains,
Methicillin-resistant S. aureus (MRSa), E. coli, P.
aeruginosa and Mycobacterium intracellulare, or used
pathogenic fungi including C. albicans, A. fumigatus
and Cryptococcus neoformans [33].
No bacterial activity has been showed in metabolites extracted from P. constellatum [33], this was
incompatibility with our study because in this
research bacterial activity of P. constellatum was
moderate toward 2 strains only of gram-positive
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bacteria: S. aureus and B. subtilis. There was agreement in no activity have appeared toward gram
negative bacteria E. coli. However, various extracts
of species from the same family exhibited mild and
moderate antibacterial activity as set [30]. As an
overview shown, ascidians have antifungal components. However, our study coincides with [33] study
owing to no activity of P. constellatum toward any
tested fungus.
3.1.3. The ascidian Styela canopus
Isolated two peptides, Styelin A and Styelin B,
from Styela clava have inhibitory activity against
pathogenic human bacteria whether Gram negative
or Gram positive, with minimal inhibitory concentrations below 1.5 mg/mL [34]. This is agreement
with our study of displaying bacterial activity of the
genus Styela. No antimicrobial activity found in
three new and ten known isolated compounds of the
Safaga Styela clava against the bacteria methicillinresistant S. aureus ATCC 43300 (MRS), E. coli ATCC
35218, Pseudomonas aeruginosa ATCC 27853, and
Mycobacterium intracellulare ATCC 23068, and against
the fungi C. albicans ATCC 90028, C. glabrata ATCC
90030, C. krusei ATCC 6258, Cryptococcus neoformans
ATCC 90113, and Aspergillus fumigatus ATCC 90906
[35].
Raslan et al. [35] study on Styela clava is incompatible with our research because of displaying of
antibacterial activity of extract belonging to Styela
Canopus (the same genus) toward S. aureus with 15
mm inhibition zone and other two bacteria as well.
There is an agreement between results of two species, Styela clava [35] and Styela canopus in this study
of no antifungal exhibition toward the fungus
Aspergillus fumigatus. Another coincidence is no
fungal activity appeared toward Candida albicans by
all investigated species as well.
3.1.4. The ascidian Didemnum sp.
Using the disk diffusion method, Didemnaketal D
isolated from Didemnum species which was collected
from Sharm El-Sheikh displayed moderate inhibitory activity against S. aureus ATCC 6538 with inhibition zone of 11 mm, whereas didemnaketal E
exhibited moderate activity against B. subtilis ATCC
CC33 with inhibition zone of 11 mm [36]. This agrees
with our study of the genus of Didemnum having
antibacterial compounds toward S. aureus and B.
subtilis. But in this study, the Port said Didemnum sp.
showed signiﬁcant activity against S. aureus with 17
mm inhibition zone, while the activity toward B.
subtilis was moderate with 10 mm inhibition zone.
Didemnaketal F isolated from Didemnum species
collected from Sharm El-Sheikh exhibited strong
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antibacterial activity against E. coli ATCC 25922 inhibition zone of 20 mm [37], while in our study,
antibacterial activity toward E. coli ATCC 25955 was
mild activity of 11 mm inhibition zone. The two
studies have agreement in showing antibacterial
activity of Didemnum species toward the same
Gram-negative bacterium.
In the study of Shaala et al. (2014) [37], the two
Didemnaketal isolated from Didemnum species
which was collected from Sharm El-Sheikh,
Didemnaketal F exhibited strong antimicrobial activity against C. albicans ATCC 14053 with inhibition
zone of 24 mm, while Didemnaketal G showed
moderate activity against C. albicans with an inhibition zone of 17 mm. On the contrary with our
research in which there is no activity displayed by
any of extracts of ascidian species toward C. albicans
ATCC 10231. In this study, no activity toward the
fungi Aspergillus ﬂavus, Candida albicans and
Penicillium expansum has been exhibited from any
tested ascidian species, which indicates to no antimicrobial components in the tested ascidians toward these fungi.
As an overall perspective, Former investigations
of anti-microbial activity of marine invertebrates
such as sponges and ascidians have manifested that
Gram-positive bacteria are more sensitive than
Gram-negative bacteria or fungi to these invertebrates extracts [38], this inclusion is in agreement with our study ﬁndings as well, from six
microbes tested, 10 activities have been displayed in
three types of Gram-positive bacteria while 12 activities have been displayed in the three types of
gram-negative bacteria and six types of fungi.
Lissoclinum patella, Didemnum molle, Family:
Didemnidae; Oxycoryna fascicularis, Family: Clavelinidae; Botryllus schlosseri, Family: Styelidae [31];
Synoicum pulmonaria [38]; Polyclinum madrasensis,
Family: Polyclinidae; Phallusia nigra, Family: Ascidiidae [30], (Bragadeeswaran et al. 2010); have activity against S. aureus (RCMB010010), Besides in
this research, all tested ascidian species in Egypt
exhibited activity against the same gram positive
bacterium, indicating the consensus between our
study and previous studies. The best activity was
shown in the Didemnum sp. (Family: Didemnidae).
As shown, Activity toward the gram positive
bacterium B. subtilis has been displayed by Lissoclinum notti [34], Lissoclinum patella (Family: Didemnidae), Oxycoryna fascicularis (Family: Clavelinidae),
Didemnum molle (Family: Didemnidae), and Botryllus
schlosseri (Family: Styelidae) [31], in our research all
examined ascidian species in Egypt shown activity
against the same Gram-positive bacterium, conﬁrming the agreement between our research and
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previous studies. The best activity was appeared in
the Didemnum sp. (Family: Didemnidae) with inhibition zone of 10 mm.
Overall, the extracts of ﬁve collected species of
ascidians in Egypt extracted by dicholoromethane
and methanol solvents at room temperature, these
ascidian ﬁve extracts from Egypt caused mild and
moderate growth inhibition of some bacterial species, whereas no effect have showed on other bacteria, suggesting that these ascidian extracts
selectively inhibit some groups of microbes.
3.2. Cytotoxic activity of ascidian
Although utilizing of marine ascidians in discovering bioactive metabolites are relatively contemporary, a number of ascidians components are being
subjected to preclinical and clinical trials as antitumor agents [39]. The studies of the United StatesNational Cancer Institute have conﬁrmed that marine invertebrates exhibit a higher percentage of
cytotoxic compounds than any other zoological
category [40], Palanisamy, Rajendran & Marino [21]
listed out 327 anti-tumor/cancer compounds that
isolated from ascidians during the years 1994e2014.
Besides, the most promising organisms that are
considered as sources for new active components to
develop drugs are sponges, tunicates, bryozoans, …
etc. [22].
Ascidian Synoicum pulmonaria (family: Polyclinidae) showed cytotoxic activity against the
human cancer cell lines A2058 (melanoma), MCF-7
and HT-29 (colon carcinoma) at an IC50 value of 30.5
mM [41]. In Korea, Extracts of Styela clava via the
MTT reduction assay have afforded the cytotoxic
impact on the human colon carcinoma (HT-29 and
SW620), human cervices adenocarcinoma (HeLa),
and (MCF-7) [42]. Both ascidian Lissoclinum patella
and Didemnum molle have been used to isolate
several cytotoxic compounds such as cyclic peptides, diterpenes, and alkaloids [43], which are
cytotoxic against different tumor cell lines and are
regarded as promising compounds for the development of new anticancer agents.
Various extracts of Polyclinum madrasensis (Family:
Polyclinidae) and Phallusia nigra (Family: Ascidiidae) obtained from Tuticorin Coast of India have
been tested at different concentrations using Brine
Shrimp Lethality Assay and exhibited highest cytotoxicity assay, conﬁrming the existence of cytotoxic
compounds in these ascidians. The different LC50
values of various solvent extracts, such as Methanol
97, Dichloromethane 79, 2- Ethoxy Ethanol 78,
Acetone 54, n-Butanol 74, Ethylacetate 21, and

Diethyl ether 43, of Polyclinum madrasensis are 97,
79, 78, 54, 74, 21, and 43 respectively. The different
LC50 values of various solvent extracts, such as
Methanol, Dichloromethane, 2- Ethoxy Ethanol,
Acetone, n-Butanol, Ethylacetate, Diethyl ether, of
Phallusia nigra are 145, 67, 35, 69, 52, 64, and 56,
respectively [30].
Natural components with cytotoxic characteristics
are in various species of ascidians. The extract
methanol extracts of both ascidian species, Didemnum psammatode and Phallusia arabica, have cytotoxic
properties against Artemia salina larvae using the
brine shrimp lethality assay which is deemed as
clear and authoritative evidence and most used in
the examination procedure to isolate the bioactive
metabolites [44]. In Egypt, the Safaga Styela clava is
utilized to isolate three new and ten known compounds. Up to the highest tested concentration of 25
mg/mL, none of these isolated compounds was
cytotoxic to four cancer cell lines SKMEL, KB, BT549 & SK-OV-3 [35]. Nine secondary metabolites
have been isolated from the ascidian Polyclinum
constellatum which was compiled at Safaga in Egypt.
None of the components was cytotoxic to four cancer cell lines (SK-MEL, KB, BT-549, SK-OV-3).
However, compound 24-methylene cholesterol
showed cytotoxicity to noncancer kidney cells LLCPK1 with IC50 value of 23 mg/mL [33].
By using MTT assay on Hep-2 human cells, IC50
for Turkish samples: Halocynthia papillosa (Family:
Pyuridae), Styela clava (Family: Styelidae), Ascidiella
aspersa (Family: Ascidiidae) is 75.86 ± 2.61,
72.64 ± 2.17, & 86.55 ± 3.69 mg/mL, respectively, in
addition Halocynthia papillosa & Ascidiella aspersa
have as well a signiﬁcant tyrosinase inhibitory activity [32]. By using the brine shrimp lethality
bioassay, the LC50 values of the extract extract of
Lissoclinum patella (Family: Didemnidae), Oxycoryna
fascicularis (Family: Clavelinidae), Didemnum molle
(Family: Didemnidae), and Botryllus schlosseri (Family: Styelidae) were 74.3, 132.91, 97.145, 114.71 mg/ml,
respectively. The most promising species are Lissoclinum patella and Didemnum molle [31].
In this study, remarkable activities (lucrative IC50)
have elucidated through cytotoxicity assay of ﬁve
ascidian species applied, Botryllus eilatensis, Didemnum sp, Polyclinum constellatum, Styela canopus, and
Symplegma rubra with IC50¼79 ± 2.9, 47.4 ± 1.4,
61 ± 0.9, 178 ± 4.8, 17.5 ± 3.2 mg/ml, respectively,
indicating the presence of cytotoxic components in
these ascidians from Egypt. More studies must be
performed to isolate these compounds and examine
their validity to use as pharmaceutical agents. Results of this study have coincided with majority of
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previous studies of conﬁrming that ascidian species
have potent cytotoxicity and are excellent marine
species to use for cancer drug development.

4. Conclusion
The ﬁve ascidian species collected from Egyptian
coasts were shown to possess activity against several
microbes and MCF-7 cells with various extents. No
activity has been displayed by any of ascidian extracts against four microbes Aspergillus ﬂavus,
Candida albicans, Penicillium expansum and Streptococcus mutants. All investigated ascidian species
(Polyclinum constellatum, Symplegma rubra, Botryllus
eilatensis, Styela canopus & Didemnum sp) have antibacterial compounds toward S. aureus and B. subtilis
that may be the same or not reliable on more studies
to conﬁrm or reject this perspective. Botryllus eilatensis was the only species that has antibacterial
compounds toward the fungus Aspergillus fumigatus.
Didemnum sp. has exhibited activity against seven
microbes from twelve used microbes, while S.
canopus, Botryllus eilatensis, S. rubra, and P. constellatum have exhibited activities against 4,5,4, & 2
microbes from twelve used microbes, respectively.
Besides, all ascidian extracts have cytotoxic components against MCF-7 cells. The most promising
species for anti-microbial and cytotoxic properties
were Didemnum sp. and Symplegma rubra, respectively. These bioactive activities indicate the promise value of these species to investigate more and
conﬁrm that ascidians represent perfect candidates
to introduce lead compounds on cancer research.

5. Materials and methods
5.1. Collection of ascidian species and
morphological identiﬁcation
Solitary and colonial ascidians were gathered by
hand from two coastal sites in Egypt. The colonial
ascidian Polyclinum constellatum was collected from
Ismailia in late October 2018, Coordinates
(30.5871030, 32.3055460), while the colonial ascidians

Botryllus eilatensis, Didemnum sp., and Symplegma
rubra; and the Solitary ascidian Styela canopus were
collected from Port Said in earlier November 2018,
coordinates (31.255452,32.314496). Ascidian samples
were transferred to laboratory in containers containing natural seawater for morphological identiﬁcation and photographing.
Morphological identiﬁcation was performed by
Dr. Gibreel Sharaf, Marine Science Department,
Faculty of Science, Suez Canal University. Washing
was preceded with tape water to remove any debris.
Samples were weighed and preserved at - 20  C
until further use.
5.2. Extraction of ascidian extracts
Every species was weighed, cut into small pieces
and separately put into a ﬂask. Equal volumes of
dichloromethane CH2CL2 and methanol MeOH
(1:1) were used to prepare the extracts, two times at
room temperature in dark place. Soaked samples
were kept for 24 hours in ﬁrst time then for 7 days in
second time. Decanted solutions of every species
were mixed together in clean beakers and evaporated completely letting extract extracts which are
collected with wooden tools and put in eppendorfs.
The cut-ascidian species were dried and weighed
(Table 1).
5.3. Evaluation antimicrobial effects of ﬁve
ascidian extracts
50 mg of each extract was dissolved in 1 ml of
dimethyl sulfoxide for evaluation of antimicrobial
activity that was assessed using the diffusion agar
technique, well diameter: 6.00 mm, 100 ml was tested,
according to guidelines of NCCLS (National Committee for clinical laboratory Standards). 100 ml was
tested via injection in well with diameter of 6.00 mm.
Screening tests regarding the inhibition zone were
carried out by the well diffusion method [45]. The
inoculum suspension was prepared from colonies
grown overnight on an agar plate and inoculated
into Mueller-Hinton broth (fungi using malt broth).

Table 1. Weights of ﬁve ascidian samples.
Species Name

Weight (gm)
(before putting in solutions)

Weight (gm)
(after soaking and drying)

Dry weight (gm)

Polyclinum constellatum
Symplegma rubra
Botryllus eilatensis
Styela canopus
Didemnum sp.

196
290
45
106
56

20
31
5.5
13.31
15

176
259
39.5
92.69
41

The examination of anti-bacterial & anti-cancer activity for the dried extract extracts was proceeded against the 6-type fungi, 6-type
bacteria, and MCF-7 cells.
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A sterile swab was immersed in the suspension
and used to inoculate Mueller-Hinton agar plates
(fungi using malt agar plates). The compounds were
dissolved in dimethyl sulfoxide with concentration
(50 mg/ml). After 24 h at 37  C, the inhibition zone
was measured around each well. Blanks using
DMSO were adequately done to ensure that no effect of used solvent on microbes. Controls are
Gentamycin in bacterial work and Ketoconazole in
fungal work were done.
5.4. Evaluation cytotoxic effects of ﬁve ascidian
extracts using crystal violet assay
Cell line Propagation: The MCF-7 cells obtained
from VACSERA Tissue Culture Unit were propagated in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 10% heat-inactivated
fetal bovine serum, 1% L-glutamine, HEPES buffer
and 50 mg/ml gentamycin that were purchased from
Lonza. All cells were maintained at 37  C in a humidiﬁed atmosphere with 5% CO2 and were subcultured two times a week.
Evaluation of cytotoxic effects for ascidian extracts
was preceded using crystal violet viability assay [46].
MCF-7 cells were seeded in 96-well plate at a cell
concentration of 1  104 cells per well in 100 ml of
growth medium. Serial two-fold dilutions were
prepared for each ascidian extract. After incubation
of the cells for 24 h at 37  C, the various concentrations that was supplemented in fresh medium
were added to conﬂuent cell monolayers dispensed
into 96-well, ﬂat-bottomed microtiter plates (Falcon,
NJ, USA) using a multichannel pipette, three wells
were set for each concentration. Control cells were
incubated without test sample and with or without
DMSO.
The microtiter plates containing MCF-7 cells with
tested extract and controls were maintained in a.
incubator (37  C, 5% CO2, humidiﬁed) for 24 h.
Viable cells yield was determined by a colorimetric
method. DMSO was found not to affect the experiment. The media were aspirated. The ﬁltered crystal
violet solution 1% through a Whatmann No.1 ﬁlter
paper that is composed of 0.5% crystal violet purchased from Sigma (St. Louis, Mo., USA), 50%
methanol and ddH2O was added to each well for at
least 30 minutes. Removing of stain and washing of
cells with tap water were peformed.
Glacial acetic acid (30%) was added to all wells.
Measuring the optical density of each well was
at 490 nm with a Microplate reader (SunRise,
TECAN, Inc, USA). All results were corrected for

background absorbance detected in wells without
added stain.
Treated samples were compared with the cell
control without the tested extracts. The number of
viable cells and the percentage of viability was
calculated as [(ODt/ODc)] x 100% where ODt is the
mean optical density of wells treated with the tested
sample and ODc is the mean optical density of untreated cells. Values of surviving cells and concentrations of ascidian extract are used to plot the
survival curve for each MCF-7 cells treated with
ascidian extract. The 50% inhibitory concentration
(IC50) was estimated from ﬁve graphic plots using
Graphpad Prism software (San Diego, CA. USA).
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